Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance Frontiers in Microbiology, March 2022, Volume 13, Article 841905
Exebacase in Addition to Daptomycin against MRSA Antimicrobial Agents & Chemotherapy, November 2021, Volume 65, Issue 11
Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection Antimicrobial Agents & Chemotherapy, September 2021, Volume 65, Issue 9
Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis Antimicrobial Agents & Chemotherapy, June 2021, Volume 65, Issue 6.
Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model Journal of Antimicrobial Chemotherapy, July 5, 2021.
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity Journal of Clinical Microbiology, July 2021, Volume 59, Issue 7
Development of a Broth Microdilution Method for Exebacase Susceptibility Testing Antimicrobial Agents & Chemotherapy, July 2021, Volume 65, Issue 7
Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Frontiers in Medicine, May 2021, Volume 8, Article 550853
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis The Journal of Clinical Investigation, Volume 130, Issue 7, July 1, 2020
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography Antimicrobial Agents & Chemotherapy, July 2020, Volume 64, Issue 7
Locally Delivered Antistaphylococcal Lysins Exebacase or CF-296 is Active in Methicillin-Resistant Staphylococcus aureus Implant-associated Osteomyelitis Presented at ASM Microbe 2022, June 12, 2022
Lysin Exebacase Has a Low Propensity for Resistance Development and Suppresses the Emergence of Resistance to Anti-Staphylococcal Antibiotics Presented at ASM Microbe 2022, April 23, 2022
Lysin CF-370 exhibits a low propensity for decreased susceptibility in Gram-negative (GN) ESKAPE pathogens Presented at ECCMID 2022, April 23, 2022
Lysin CF-370 suppresses in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin Presented at ECCMID 2022, April 23, 2022
Direct lytic agents, a novel family of antimicrobial agents, have a low propensity for decreased susceptibility in Gram-negative pathogens associated with airway infection in Cystic Fibrosis Presented at ECCMID 2022, April 23, 2022
In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections Presented at ECCMID 2022, April 23, 2022
Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci Presented at ECCMID 2022, April 23, 2022
Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots Presented at ECCMID 2022, April 23, 2022
Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans Presented at North American Cystic Fibrosis Conference 2021, November 2, 2021
In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets Presented at ID Week 2021, September 29, 2021